UTHR – United Therapeutics Corporation
United Therapeutics CorporationUTHR
$355.93Name : United Therapeutics Corporation
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $15,835,752,448.00
EPSttm : 21.75
United Therapeutics Corporation
$355.93
1.67%$5.86Fair Value
433.39
Margin Of Safety %
22
Put/Call OI Ratio
1.43
Float Short %
9.35
EPS 1 Diff
0.7
EPS Year Diff
3.64
Ticker: UTHR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-09-06 | UTHR | 345.45 | 1.49 | 1.07 | 7271 |
| 2024-09-09 | UTHR | 347.52 | 1.51 | 2.27 | 7433 |
| 2024-09-10 | UTHR | 342.53 | 1.52 | 1.20 | 7538 |
| 2024-09-11 | UTHR | 346.2 | 1.55 | 0.36 | 7567 |
| 2024-09-12 | UTHR | 341.1 | 1.55 | 17.50 | 7575 |
| 2024-09-13 | UTHR | 338.98 | 1.60 | 15.79 | 7726 |
| 2024-09-16 | UTHR | 344.85 | 1.66 | 1.04 | 7941 |
| 2024-09-17 | UTHR | 344.91 | 1.67 | 0.15 | 7996 |
| 2024-09-18 | UTHR | 342.56 | 1.65 | 0.18 | 8030 |
| 2024-09-19 | UTHR | 351.47 | 1.66 | 0.78 | 8013 |
| 2024-09-20 | UTHR | 353.03 | 1.69 | 0.14 | 8057 |
| 2024-09-23 | UTHR | 355.8 | 1.36 | 4.61 | 6262 |
| 2024-09-24 | UTHR | 357.8 | 1.40 | 3.41 | 6386 |
| 2024-09-25 | UTHR | 359.74 | 1.42 | 0.43 | 6436 |
| 2024-09-26 | UTHR | 356.72 | 1.41 | 0.48 | 6456 |
| 2024-09-27 | UTHR | 358.77 | 1.41 | 1.82 | 6431 |
| 2024-09-30 | UTHR | 358.14 | 1.42 | 0.95 | 6460 |
| 2024-10-01 | UTHR | 357.85 | 1.42 | 0.94 | 6494 |
| 2024-10-02 | UTHR | 352.22 | 1.42 | 0.31 | 6477 |
| 2024-10-03 | UTHR | 349.95 | 1.43 | 0.80 | 6449 |
| 2024-10-04 | UTHR | 355.74 | 1.43 | 0.00 | 6456 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-09-06 | UTHR | 345.63 | 19.3 | 7.0 | 24.75 |
| 2024-09-09 | UTHR | 348.47 | 19.3 | 44.7 | 24.75 |
| 2024-09-10 | UTHR | 342.46 | 19.3 | -1.4 | 24.75 |
| 2024-09-11 | UTHR | 346.14 | 19.3 | 49.4 | 24.75 |
| 2024-09-12 | UTHR | 341.09 | 19.3 | 4.2 | 24.75 |
| 2024-09-13 | UTHR | 339.13 | 19.3 | 20.0 | 24.75 |
| 2024-09-16 | UTHR | 344.75 | 19.3 | 59.8 | 24.75 |
| 2024-09-17 | UTHR | 344.95 | 19.3 | 29.7 | 24.75 |
| 2024-09-18 | UTHR | 342.28 | 19.3 | 16.3 | 24.75 |
| 2024-09-19 | UTHR | 351.40 | 19.3 | 76.0 | 24.75 |
| 2024-09-20 | UTHR | 353.01 | 19.3 | 38.8 | 24.77 |
| 2024-09-23 | UTHR | 355.60 | 19.3 | 43.2 | 24.77 |
| 2024-09-24 | UTHR | 357.91 | 19.3 | 41.8 | 24.77 |
| 2024-09-25 | UTHR | 359.61 | 19.3 | 38.6 | 24.77 |
| 2024-09-26 | UTHR | 357.72 | 18.4 | 21.6 | 24.68 |
| 2024-09-27 | UTHR | 358.53 | 18.4 | 34.3 | 24.68 |
| 2024-09-30 | UTHR | 358.13 | 18.4 | 28.4 | 24.68 |
| 2024-10-01 | UTHR | 357.87 | 18.4 | 29.0 | 24.68 |
| 2024-10-02 | UTHR | 352.53 | 18.4 | 4.3 | 24.68 |
| 2024-10-03 | UTHR | 349.88 | 18.4 | 17.3 | 24.68 |
| 2024-10-04 | UTHR | 355.83 | 18.4 | 59.3 | 24.68 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-09-06 | UTHR | -51.74 | 1.02 | 9.47 |
| 2024-09-09 | UTHR | -50.91 | 1.02 | 9.47 |
| 2024-09-10 | UTHR | -51.15 | 1.02 | 9.47 |
| 2024-09-11 | UTHR | -51.15 | 1.02 | 9.47 |
| 2024-09-12 | UTHR | -50.21 | 1.02 | 9.35 |
| 2024-09-13 | UTHR | -50.21 | 1.02 | 9.35 |
| 2024-09-16 | UTHR | -48.05 | 1.02 | 9.35 |
| 2024-09-17 | UTHR | -48.05 | 1.02 | 9.35 |
| 2024-09-18 | UTHR | -48.32 | 1.02 | 9.35 |
| 2024-09-19 | UTHR | -48.32 | 1.02 | 9.35 |
| 2024-09-20 | UTHR | -48.32 | 1.02 | 9.35 |
| 2024-09-23 | UTHR | -47.05 | 1.02 | 9.35 |
| 2024-09-24 | UTHR | -47.05 | 1.02 | 9.35 |
| 2024-09-25 | UTHR | -47.33 | 1.02 | 9.35 |
| 2024-09-26 | UTHR | -46.24 | 1.02 | 9.35 |
| 2024-09-27 | UTHR | -46.24 | 1.02 | 9.35 |
| 2024-09-30 | UTHR | -43.94 | 1.02 | 9.35 |
| 2024-10-01 | UTHR | -43.94 | 1.02 | 9.35 |
| 2024-10-02 | UTHR | -44.25 | 1.02 | 9.35 |
| 2024-10-03 | UTHR | -44.25 | 1.02 | 9.35 |
| 2024-10-04 | UTHR | -43.03 | 1.02 | 9.35 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
5.85
Avg. EPS Est. Current Quarter
6.37
Avg. EPS Est. Next Quarter
6.55
Insider Transactions
-43.03
Institutional Transactions
1.02
Beta
0.57
Average Sales Estimate Current Quarter
724
Average Sales Estimate Next Quarter
730
Fair Value (Academic)
395.76
Quality Score
99
Growth Score
88
Sentiment Score
21
Actual DrawDown %
2.8
Max Drawdown 5-Year %
-31.2
Target Price
368
P/E
16.35
Forward P/E
12.65
PEG
0.93
P/S
6.05
P/B
2.78
P/Free Cash Flow
17.98
EPS
21.77
Average EPS Est. Cur. Y
24.68
EPS Next Y. (Est.)
27.08
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
40.87
Relative Volume
0.33
Return on Equity vs Sector %
-2.8
Return on Equity vs Industry %
-24
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.07
EBIT Estimation
59.3
United Therapeutics CorporationSector: Healthcare
Industry: Biotechnology
Employees: 1168
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
stock quote shares UTHR – United Therapeutics Corporation Stock Price stock today
news today UTHR – United Therapeutics Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch UTHR – United Therapeutics Corporation yahoo finance google finance
stock history UTHR – United Therapeutics Corporation invest stock market
stock prices UTHR premarket after hours
ticker UTHR fair value insiders trading